

### STRUCTURING A TELEHEALTH EVALUATION

**JUNE 2020** 

### **EVALUATION STRATEGY: OVERVIEW**

### Research suggests a four-step process for measuring the efficacy of telehealth

### **Evaluability**

- Assessment conducted prior to or at the beginning of a program to make explicit the goals and objectives of the program and intended effects or outcomes.
- Key components include: (1) framing the research question, (2) determining research design, (3) identifying data collection methods, and (4) determining the analytic method.

#### **Documentation**

- Narrative that describes the implementation of the program.
- Documentation should include the procedures used, the difficulties encountered, the steps taken to address barriers, successes/challenges in dealing with those barriers, and how the program can be reproduced in another setting.

# Formative evaluation

- Evaluation focusing on the process of the program being delivered.
- Formative evaluations allows for project managers to observe attitudinal changes related to the program, any workforce integration issues, and potential technical issues with program rollout.

# Summative evaluation

- Evaluation providing evidence of the intended effects of the program.
- The goal of a summative evaluation is to provide robust evidence of a program, identify the benefits of the program, and provide evidence to policy and decision makers.

<sup>1.</sup> Agboola, Stephen et al., "'Real-World' Practical Evaluation Strategies: A Review of Telehealth Evaluation," JMIR Research Protocols, Vol. 3(4), 2014.



### EVALUATION STRATEGY: CODIFYING THE PROGRAM MODEL<sup>1</sup>

"Telehealth" can mean many different things, so establishing a clear program model is vital prior to conducting an evaluation

### What are the goals of the program?

- As a first step, program staff should define the primary goals and objectives of the telehealth program.
  - Objectives can include improving clinical outcomes, increasing engagement, and decreasing costs and most likely all three.
- Project coordinators should identify and ensure access to the data needed to measure the goals and the
  objectives of the telehealth program.
  - Data sources can include electronic health records, Medi-Cal claims data, and patient surveys.
- Attention should be paid to the questions that senior stakeholders and decision-makers will want to have answered, as these individuals will determine the rate of scale if successful.

### How is the program structured?

- Program staff should clearly define each component of the program model:
  - Who is the target population being served?
  - Who delivers services, and what are the required qualifications?
  - Who are the major stakeholders, and what is their role?
  - What is the timeline for services? When do you expect to be able to measure clinical outcomes?
- Performance indicators should be generated for each step in the process.



### **OUTCOME METRICS: PROCESS AND SUMMATIVE EVALUATION**

#### Formative evaluation<sup>1</sup>

What questions need to be answered to ensure that the program is functioning appropriately and engaging individuals?

- Was the target audience appropriately reached?
- Has the program been adopted by key stakeholders?
- Are key stakeholders engaged?
- Are engagement patterns different based on time, demographic group, or location?
- Are some participants responding differently to engagement techniques than others?
- Are ongoing troubleshooting issues reported and addressed promptly?

#### Summative evaluation

What questions need to be answered to ensure that the program is improving outcomes for individuals?

# Example outcome metrics for different populations may include:

- Substance use disorder: changes in ED visits or hospitalizations due to substance use<sup>2</sup>
- Veterans with PTSD: changes in the clinician-administered PTSD scale<sup>3</sup>
- Individuals with SMIs: change in psychiatric symptoms (e.g., psychosis and depression), health outcomes (weight, blood pressure), ED visits and/or hospitalizations due to SMIs<sup>4</sup>

<sup>4.</sup> Pratt, Sarah I et al., "Feasibility and Effectiveness of an Automated Telehealth Intervention to Improve Illness Self-Management in People With Serious Psychiatric and Medical Disorders", Psychiatric Rehabilitation Journal, Vol. 36(4), December 2013.



<sup>1.</sup> Agboola, Stephen et al., "'Real-World' Practical Evaluation Strategies: A Review of Telehealth Evaluation," JMIR Research Protocols, Vol. 3(4), 2014.

<sup>2.</sup> Huskamp, Haden et al., "How Is Telemedicine Being Used In Opioid and Other Substance Use Disorder Treatment?", Health Affairs, Vol. 37(12), December 2018.

<sup>3.</sup> Morland, Leslie A et al., "Group Cognitive Processing Therapy Delivered to Veterans via Telehealth: A Pilot Cohort," Journal of Traumatic Stress, Vol. 24(4), August 2011.

### DATA SOURCES FOR MEASUREMENT

# Summative evaluations will require access to administrative physical and behavioral health data

Data source	Primary use	Evaluation type
Patient survey	<ul> <li>Used to measure client satisfaction with services.</li> <li>Can be particularly helpful for telehealth to measure the setup (e.g., technology) and engagement on the part of the client and clinician.</li> <li>Not useful to measure clinical outcomes.</li> </ul>	Formative
Electronic health records <sup>1</sup>	<ul> <li>Contain a patient's medical history, diagnoses, treatment plans, immunization dates, etc.</li> <li>Provider notes can provide context on telehealth sessions and scores on different psychiatric rubrics.</li> <li>Will include most of the medical data that is used make clinical decisions, but may not be as easy to code for summative evaluation.</li> </ul>	Formative, summative
Insurance (e.g., Medi- Cal) claims data	<ul> <li>Will contain each instance that an individual is billed for a medical service.</li> <li>Helpful for understanding both utilization and cost patterns.</li> <li>Will not necessarily provide context on the specific reason for an incident.</li> </ul>	Summative



<sup>1. &</sup>quot;What is an electronic health record (EHR)?", HealthIT.gov.

### POTENTIAL RESEARCH PARTNERS




Partner with California's state and local governments to generate scientific evidence that solves California's most urgent problems



Clinical and Translational
Science Center

Serves as a catalyst to support biomedical research projects by providing services and resources to investigators, staff, scholars and trainees, and community partners.

# ► APPENDIX: EVALUATION DESIGNS



### TYPES OF EVALUATION DESIGNS

### **Observational**

Compares participants' outcomes at program beginning and end; can be averaged to measure the group's overall change

- Least rigorous
- Example: pre/post analysis

### **Quasi-Experimental**

Compares treatment group with a comparison group without randomizing; can be achieved via matching like individuals or comparing like groups

- Less rigorous than experimental design
- Examples: Propensity score matching, regression discontinuity


### **Experimental**

Randomly assigns individuals to treatment and control groups, effectively controlling for selection bias

- Operationally complex, introduces ethical concerns
- Rigorous, attribute causality
- Example: Randomized controlled trials (RCTs)

### Operational resources needed

### **Evaluation rigor**





High level

## OVERVIEW OF EVALUATION METHODS

Evaluation method	Definition	Strengths	Weaknesses
Randomized Controlled Trial (RCT)	Randomly assign target population to treatment and control groups to isolate intervention effects	<ul> <li>Considered most credible</li> <li>Clear distinction between treatment and control groups</li> <li>Simple to interpret</li> </ul>	<ul> <li>Potential ethical concerns</li> <li>Operationally complex to set-up</li> <li>Potential strict research protocols</li> </ul>
Quasi- experimental design (QED): Regression discontinuity	Use a threshold to assign contemporaneous treatment and comparison groups and estimate the marginal impact of being near a cutoff	<ul> <li>Closest substitute to randomization</li> <li>Assumes that those who just barely received treatment are comparable to those who just barely did not receive treatment</li> </ul>	<ul> <li>Can't extrapolate findings beyond narrow bandwidth (less precise further away from cutoff)</li> <li>Difficult to find large enough sample near the threshold to estimate precise results</li> </ul>
QED: Matching	Match program participants with non-treated, contemporaneous "control" group using demographic variables	<ul> <li>Can build on existing evaluations and assumptions to inform evaluation design</li> <li>Can be conducted retrospectively</li> <li>Easier to obtain stakeholder buy-in</li> </ul>	<ul> <li>Potential for selection bias cannot control for unobservable characteristics</li> <li>Difficult to achieve baseline equivalence between groups (may need large comparison sample)</li> </ul>
QED: Difference- in-differences	Compare before-and-after effects for a group or region of intervention participants vs nontreated group or region	<ul> <li>Relatively simple to calculate; can be calculated with a single, basic regression</li> </ul>	<ul> <li>Relies heavily on assumption that absent the program groups would have had "parallel trends"</li> </ul>
Historical baseline	Compare outcomes of intervention participants to incidence of outcome in a historical group	<ul> <li>Less operationally complex and costly</li> </ul>	<ul> <li>High potential for selection bias</li> <li>Policy changes that have occurred may skew observed results</li> <li>Not very rigorous</li> </ul>